Repare Therapeutics: Canadian Nuclear Laboratories Announces Collaboration with Repare Therapeutics and Defence Therapeutics on Individual Research Projects Through (CRHI-H) Program

Canadian Nuclear Laboratories (CNL) announced that it is collaborating with two leading Canadian healthcare biotech companies ? Repare Therapeutics and Defence Therapeutics ? . Launched in 2021, the CNRI-H program is designed to accelerate the development of targeted radiopharmaceuticals in Canada through joint research projects related to oncology, targeted alpha therapy, radiopharmaceuticals and medical isotope development. Repare and CNL plan to leverage the strengths of both organizations which cut across radiobiology, preclinical evaluation, and the discovery of therapeutics that kill cancer cells by stopping the repair of DNA in cancer cells. This work will potentially generate more insight into repair mechanisms associated with radiation induced damage in DNA of cancer cells and hopefully lead to the development of therapeutics that can significantly enhance current radioligand therapies in cancer treatment for the benefit of Canadians and the world. CNL?s project with Defence Therapeutics leverages the capabilities at CNL to advance Defence?s Accum® Technology to deliver auger electron (AE) emitting isotopes as close to the nucleus as possible. Research has already shown that delivering AE-emitting isotopes to the nucleus can deliver significant damage to cancer cells. Successful deployment of this project?s delivery system could unlock the full potential of AEs in cancer treatment. Canadian Nuclear Laboratories (CNL) announced that it is collaborating with two leading Canadian healthcare biotech companies ? Repare Therapeutics and Defence Therapeutics ? . Launched in 2021, the CNRI-H program is designed to accelerate the development of targeted radiopharmaceuticals in Canada through joint research projects related to oncology, targeted alpha therapy, radiopharmaceuticals and medical isotope development. Repare and CNL plan to leverage the strengths of both organizations which cut across radiobiology, preclinical evaluation, and the discovery of therapeutics that kill cancer cells by stopping the repair of DNA in cancer cells. This work will potentially generate more insight into repair mechanisms associated with radiation induced damage in DNA of cancer cells and hopefully lead to the development of therapeutics that can significantly enhance current radioligand therapies in cancer treatment for the benefit of Canadians and the world. CNL?s project with Defence Therapeutics leverages the capabilities at CNL to advance Defence?s Accum® Technology to deliver auger electron (AE) emitting isotopes as close to the nucleus as possible. Research has already shown that delivering AE-emitting isotopes to the nucleus can deliver significant damage to cancer cells. Successful deployment of this project?s delivery system could unlock the full potential of AEs in cancer treatment.